Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon beta-1a in primary progressive multiple sclerosis.

Siobhan M Leary1, Alan J Thompson

  • 1NMR Research Unit, Institute of Neurology, University College London, Queen Square, WC1N 3BG, London, UK. siobhan_leary@hotmail.com

Journal of the Neurological Sciences
|February 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026
Same author

Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis - Authors' reply.

The Lancet. Neurology·2026
Same author

Anti-Nogo-A NG101 treatment induces changes in spinal cord micro- and macrostructure following spinal cord injury.

Nature communications·2026
Same author

Performance of the 2024 McDonald Criteria in Patients Under Evaluation for Suspected Multiple Sclerosis.

Neurology·2026
Same author

Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2025
Same author

Single-centre, prospective cohort to predict optimal individualised treatment response in multiple sclerosis (POINT-MS): a cohort profile.

BMJ open·2025
Same journal

Subjective cognitive decline among U.S. Cancer survivors, 2017-2024: Prevalence, cancer-specific patterns, and associated factors.

Journal of the neurological sciences·2026
Same journal

Comment on "Comparative impact of mental and cardiovascular comorbidities on adverse outcomes in people with MS".

Journal of the neurological sciences·2026
Same journal

Comment on "Efficacy and safety of conventional immunosuppressant therapies in elderly patients with Neuromyelitis optica spectrum disorder: A target trial emulation study".

Journal of the neurological sciences·2026
Same journal

Increasing incidence of varicella-zoster virus meningitis in Japan, 2011-2022.

Journal of the neurological sciences·2026
Same journal

Comment on "Excellent agreement between automated deep learning-based and manual diffusion-weighted imaging infarct volume measurements in hyperacute stroke".

Journal of the neurological sciences·2026
Same journal

Shifting from alteplase to tenecteplase in acute ischemic stroke: Progress, promise, and perils.

Journal of the neurological sciences·2026
See all related articles

Currently, no effective disease-modifying treatments exist for primary progressive multiple sclerosis (PPMS). Research is expanding, with trials like interferon beta-1a offering hope for future therapeutic advancements in PPMS.

Area of Science:

  • Neuroimmunology
  • Clinical neurology

Background:

  • Primary progressive multiple sclerosis (PPMS) lacks proven disease-modifying treatments.
  • Therapeutic options for PPMS patients are limited, necessitating further research and clinical trials.

Purpose of the Study:

  • To review the current landscape of therapeutic trials for primary progressive multiple sclerosis (PPMS).
  • To discuss a specific randomized controlled trial involving interferon beta-1a for PPMS.

Main Methods:

  • Review of recent therapeutic trials specifically designed for PPMS patients.
  • Focus on a randomized controlled trial of interferon beta-1a.

Main Results:

  • The abstract does not contain specific results from the interferon beta-1a trial.

Related Experiment Videos

  • Highlights the ongoing development of therapeutic strategies for PPMS.

    • Conclusions:

    • There is an unmet need for effective disease-modifying treatments in PPMS.
    • The development of therapeutics for PPMS is an active area of research with ongoing clinical trials.